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Pathology, MIND Institute, University of California at Davis, Sacramento, CaliforniaABSTRACT Deposition of amyloid fibrils, consisting primarily of Ab40 and Ab42 peptides, in the extracellular space in the brain
is a major characteristic of Alzheimer’s disease (AD). We recently developed new (to our knowledge) drug candidates for AD that
inhibit the fibril formation of Ab peptides and eliminate their neurotoxicity. We performed all-atom molecular-dynamics simula-
tions on the Ab42 monomer at its a-helical conformation and a pentamer fibril fragment of Ab42 peptide with or without LRL and
fluorene series compounds to investigate the mechanism of inhibition. The results show that the active drug candidates,
LRL22 (EC50 ¼ 0.734 mM) and K162 (EC50 ¼ 0.080 mM), stabilize hydrophobic core I of Ab42 peptide (residues 17–21) to its
a-helical conformation by interacting specifically in this region. The nonactive drug candidates, LRL27 (EC50 > 10 mM) and
K182 (EC50 > 5 mM), have little to no similar effect. This explains the different behavior of the drug candidates in experiments.
Of more importance, this phenomenon indicates that hydrophobic core I of the Ab42 peptide plays a major mechanistic role in the
formation of amyloid fibrils, and paves the way for the development of new drugs against AD.INTRODUCTIONMany human diseases, including amyloidoses and some
neurodegenerative diseases, have been related to the confor-
mational change of a protein or a protein fragment from its
native structure into insoluble fibrils (1–3). Among these,
Alzheimer’s disease (AD) is considered to be the most
prevalent form of age-dependent dementia. Its major char-
acteristic is the deposition of stable, ordered, filamentous
aggregates in the brain, which are commonly known as
amyloid fibrils. These fibrils consist primarily of 40- and
42-residue amyloid b (Ab) proteins, which are the endopro-
teolytic cleavage product of the amyloid b-protein precursor
(AbPP) (4). Like many other amyloid fibrils, the Ab fibrils
assume cross b-pattern structures (5).
Researchers have been investigating the properties and
causes of AD for approximately a century (6). The aggrega-
tion of Ab proteins is considered to play an essential role in
the pathogenesis of AD (7–14). It was recently found that
the neurotoxicity of AD is the result of soluble oligomers
and fibril intermediates (protofibrils) (15, 16), and is more
strongly correlated with aggregative ability than secondary
structure (17).
To date, the cause of amyloid fibril formation in vivo is
not completely clear. In vitro agitation and/or the presence
of preformed fibers have been found to promote fibril forma-
tion. Ab proteins are believed to be unstructured in aqueous
solution in the absence of organic molecules (18). However,
in the presence of tetrafluoroethylene or sodium dodecyl
sulfate (conditions thought to mimic the membrane-associ-
ated Ab proteins in the cellular environment), Ab proteins
adopt predominantly a-helical conformations (19, 20). ItSubmitted April 29, 2010, and accepted for publication December 22, 2010.
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undergo conformational changes and self-assemble into
soluble oligomers that eventually aggregate to form insol-
uble fibrils. Circular dichroism spectroscopy experiments
at pH 7.5 and 22C in aqueous solution indicated that the
intermediates in amyloid fibril formation are mainly
unfolded, and an increase in a-helix content during the fi-
brillogenesis of Ab proteins was followed by a rapid
increase in b conformation (21). Thus, stabilization of the
a-helix conformation may help to inhibit amyloid fibril
formation.
Ab42 (DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAI
IGLMVGGVVIA) is a 42-residue protein. The Ab40 variant
is shorter because it is missing two hydrophobic amino acids
(Ile and Ala) at the C-terminus, and thus is less prone to
aggregate (22,23). Earlier molecular-dynamics (MD) simu-
lation studies showed that Ab10-35 has no clear structural
preference in aqueous solutions (24). Further studies re-
vealed a stable hydrophobic core LVFFA (17–21) and
a VGSN (24–27) b-turn that is stabilized by the salt bridge
between D23 and K28 (25). Recent studies on truncated Ab
proteins indicated that residues 17–21 and 30–35 are the
important regions for promoting Ab aggregation and are
responsible for the neurotoxicity because of their high
propensity to aggregate (17,26).
Two main approaches are used for the development of
AD drugs (6). One is to modulate the processing of AbPP
and the production and clearance of Ab proteins. The other
is to directly inhibit the amyloid formation of Ab proteins.
The latter process has gone through two different stages.
Initially, investigators focused on developing drugs that
could inhibit fibril formation, and mainly used the Ab40
protein as the target. Recently, however, it was discovered
that amyloid fibrils are formed through oligomeric Abdoi: 10.1016/j.bpj.2010.12.3741
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FIGURE 1 Structures of the compounds studied in this work: (a) LRL22,
(b) LRL27, (c) K162, and (d) K182. (e) NMR structure of Ab42 pentamer.
(f) NMR structure of Ab42 monomer.
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meric fibrils. Also the Ab42 protein goes through a different
oligomeric process than Ab40 proteins, in which protofibril-
type oligomers are formed. This more-amyloidogenic
character makes Ab42 more neurotoxic than Ab40 (15,16).
Therefore, the second, ongoing stage of drug discovery for
AD is focused on how to inhibit oligomer formation using
Ab42 as the target. Currently, two main strategies are used
to look for potential drugs. One is to use structural similar-
ities and aromatic interactions to look for small peptides
or polymers, such as polyphenols (27) and compounds
composed of a molecular recognition element (KLVFF)
(28), that can bind to the b-sheet to inhibit the formation
of aggregates. The other approach is to stabilize the mono-
mer native conformation of Ab proteins to prevent fibril
formation. Examples of this approach include the utilization
of the inhibitive effect of inorganic phosphate when it binds
to the native structure of Ab proteins (29), and a derivative
of ferulic acid and styryl benzene that has been shown to
bind to nonfibrous monomer-like Ab42 (30). Recently,
Nerelius et al. (31) showed that ligands that specifically
bind to the region of residues 13–26 of the Ab protein are
able to stabilize the helical conformation and reduce poly-
merization and toxicity in vitro and in vivo.
Investigators have recently discovered a series of prom-
ising active compounds from 9366 compounds of 10 combi-
natorial libraries by using high-throughput, cell-based
assays. These active compounds are able to inhibit the
formation of amyloid oligomers and fibrils, and reduce their
neurotoxicity. Some of these compounds can also pass the
blood-brain barrier, making them potential drug candidates
for AD. The four compounds we studied belong to two
different series: the LRL series (H. S. Hong, R. Liu, K. S.
Lam, and L. W. Jin, unpublished) and the fluorene series
(33) (see Fig. 1, a–d). Compound LRL22 is an active drug
candidate against AD in vitro. It is able to pass the blood-
brain barrier and has an EC50 value of 0.734 mM. Compound
LRL27 is very similar in structure to LRL22, with a slight
difference in the bromine atom position. However, LRL27
is nonactive in vitro, with EC50 > 10 mM. The fluorene
series compounds are termed K162 and K182. K162 is
significantly more potent, with an EC50 of 0.080 mM, and
K182 has an EC50 > 5.0 mM. The high degree of similarity
within each series of compounds and the notably different
activities present an interesting subject to study. Our goal
in this work was to understand what causes these differ-
ences, and to shed some light on the future development
of AD drugs.MATERIALS AND METHODS
The focus of this study is to show how the above-described compounds
influence the Ab42 protein and its oligomers. Each system includes the
Ab42 monomer, which has an initial structure in a-helix form, and four
molecules of one drug compound that are placed randomly around the
monomer at a minimum distance of 10 A˚ to allow the peptide to relaxand sample other conformations. A helical conformation (PDB code
1Z0Q (34) (Fig. 1 f) was chosen for the initial structure of Ab42 monomer
in our simulation. For the purpose of comparison, we also carried out simu-
lations in the absence of any compound. We conducted four simulations of
80 ns for each system, using the same initial structure but different veloc-
ities, and choosing different random numbers of seeds.
We included results from simulations of Ab oligomer in the presence of
drug compounds. Because it is difficult to detect the Ab oligomer directly,
to date there is no consensus regarding its structure (35). In a study using
high-resolution atomic force microscopy, Mastrangelo et al. (36) proposed
that low-weight oligomers are in fact structured and their topology is very
similar to that observed in mature fibrils. On the basis of this finding, we
chose an NMR structure of a pentamer in AD fibrils (PDB code 2BEG
(5)) as a model of soluble low-weight oligomers (Fig. 1 e). This pentamer
is constructed by five b hairpins stacked together by backbone hydrogen
bonds. Each b hairpin includes residues 17–42 of Ab42 protein because
the N-terminal is not structured. Each system consists of one Ab42 pentamer
and five molecules of one drug compound that are placed randomly around
the oligomer at a minimum distance of 10 A˚. Please note that the model we
chose for Ab oligomer is not meant to represent all possible forms of olig-
omers. Our intention is solely to provide some type of comparison of the
effects of drug compounds on Ab monomers and oligomers.
The AMBER software package (37,38) was used for both the MD simu-
lations and data processing. Proteins were represented using the AMBER
FF03 force field. The drug compounds were represented using the AMBER
generalized force field (39) for organic molecules. The structures of drug
compounds were built using GaussView (40) and optimized at
HF/6-31G* level of theory to obtain the initial structures for dynamics
studies and for charge fitting. Partial charges for the drug compounds
were fitted to the electrostatic potential at HF/6-31G** level of theory.
During the MD simulations, all systems were subjected to periodic
boundary conditions via both minimum image and discrete Fourier trans-
form as part of the particle-mesh Ewald method (41). The systems were
then immersed into a TIP3P (42) Octahedron box. The dimensions of the
box were chosen to ensure that there would be a 12.0 A˚ distance between
the protein-compound complex and the edge of the box. The systems
were then subjected to a two-step minimization. First, the protein-
compound complexes were fixed to minimize the water molecules forBiophysical Journal 100(4) 1076–1082
1078 Li et al.4000 steps. Then the complete systems were minimized without any
restrain for 20,000 steps. After minimization was completed, MD simula-
tions were performed under NPT conditions using the PMEMD (43)
program in Amber package. The first 200 ps were used to equilibrate the
system to adjust the system size and density. We then conducted 80 ns simu-
lations at 300 K in the NPT ensemble with a step size of 2 fs. The particle-
mesh Ewald (41) method was used to treat the long-distance interactions.
SHAKE (44) was applied to constrain all covalent bonds involving
hydrogen atoms. Temperature was controlled at 300 K by means of Ander-
sen’s algorithm (45). The center-of-mass translation and rotation were
removed every 500 steps, because studies have shown that this removes
the block-of-ice problem (46,47). The trajectories were saved at 2.0 ps
intervals for further analysis. All molecules that were present in the simu-
lations were subjected to analysis. All analyses of the Ab protein were done
for the last 20 ns of each simulation run.FIGURE 2 The four most populated clusters for each system: (a) Ab42
protein alone, (b) Ab42 protein with compound LRL22, (c) Ab42 protein
with compound LRL27, (d) Ab42 protein with compound K162, and (e)
Ab42 protein with compound K182. The red color represents the hydro-
phobic core I from residue 17 to residue 21, and orange represents the
hydrophobic core II from residue 30 to residue 35.
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FIGURE 3 Average percentage of adopting a helical conformation for
the complete protein chain and the hydrophobic core I (residues 17–21)
and hydrophobic core II (residues 30–35) regions.RESULTS AND DISCUSSION
Interaction between the Ab monomer
and the drug candidates
We carried out simulations to investigate the effect of each
compound on the Ab42 monomer. The systems were started
with the monomer at its a-helical conformation as seen in
the NMR structure (PDB code 1Z0Q (34)). Four molecules
of one drug compound were initially randomly positioned
10 A˚ away from the monomer. Four trajectories of 80 ns
were carried out for each compound-Ab42 monomer
mixture, resulying in a total of 320 ns of simulation for
each system. We used the last 20 ns of simulation of each
trajectory to perform the clustering analysis to identify
the substrates sampled during the simulations. The segment
of residue 13–35 was used for the clustering because the
N- and C-terminals are unstructured in water (34). The
four most populated clusters for each system are shown in
Fig. 2, in which hydrophobic core I, consisting of residues
17–21 is shown in red, and hydrophobic core II, consisting
residues 30–35, is shown in orange. These four clusters
account for ~98% of the snapshots in each system.
The Ab42 monomer alone (without the compounds)
mainly adopts a random coil with little helix sediment
(Fig. 2 a). This observation is consistent with previous exper-
imental and theoretical results (18). In the presence of
compounds, the behavior of the Ab protein can be catego-
rized into two groups. In the presence of LRL22, K162, or
K182, the Ab protein is able to retain partial helical confor-
mation in the hydrophobic core I region (Fig. 2, b–d). These
three compounds have different degrees of activity toward
the amyloid fibrils in experiments, with EC50 ¼ 0.734 mM,
0.080 mM, and >5 mM, respectively. In contrast, when
LRL27 is present, the Ab protein retains very little helical
conformation, particularly in the hydrophobic core I region.
None of the drug compounds showed a significant effect in
stabilizing the hydrophobic core II region.
We calculated the average percentage time in the last 20
ns of the simulations of the residues in the helical conforma-
tion for the complete peptide chain and the two hydrophobic
core regions (Fig. 3). The quantities plotted in Fig. 3 areBiophysical Journal 100(4) 1076–1082calculated from the percentage of the backbone fj angle
that falls in the Ramanchandran helical region, and averaged
over the residues. As shown in Fig. 3, in terms of average
percentage time for adopting the helical conformation, the
five different systems are similar when the entire protein
is considered. Therefore, the efficiency of a compound
against AD is not related to this property. However, notable
differences can be observed in the hydrophobic core I region
(residues 17–21). Specifically, in the presence of the
compounds (LRL22, K162, and K182), the helicity is
clearly increased by 60%, 43%, and 31%, respectively,
compared with that observed in the protein alone. In
contrast, in the presence of the compound (LRL27), the
A-b Drug Candidates 1079helicity is decreased by 13%. This observation is consistent
with the experimental finding that residues 17–21
(LVFFAE) play a crucial role in the neurotoxicity and
formation of amyloid fibrils (17,26). Although the hydro-
phobic core II region (residues 30–35) has also been sug-
gested to play an important role in Ab aggregation (17),
there is no consensus regarding the influence of the drug
compounds in this region.
We calculated the interaction maps between each amino
acid in Ab42 protein and each compound molecule (Fig. 4).
An interaction was defined as one in which the distance
between two atoms was within the 3.5 A˚ range. If any atom
on an amino acid contacted any atom of the compound mole-
cule, the corresponding amino acid was considered to have
one contact with the compound. In Fig. 4, a, interactions
between the two LRL series compounds and Ab42 protein
are preferentially in two regions of the protein: hydrophobic
cores I (residues 17–20) and II (residues 30–35). These two
compounds show comparable patterns in binding to Ab42FIGURE 4 (a) Map of interactions between each compound and the Ab42
monomer. The horizontal axis is the sequence number of the atoms in each
compound, and the vertical axis is the residue number in the Ab42 peptide.
The corresponding compounds are (b) LRL22, (c) LRL27, (d) K162, and
(e) K182. Carbons are in gray, oxygens are in red, nitrogens are in blue,
bromines are in pink, and hydrogens are in white. The interaction map
layout corresponds to the compound layout below it.monomer. In Fig. 4, a, it is clear that K162 interacts with
the protein in the region of hydrophobic core I to a greater
degree. At the same time, it has interactions both downstream
and upstream of this region, which may contribute to its
ability to stabilize the helical conformation in the hydro-
phobic core I region in Ab42 protein. Region I of the K162
compound plays the most important role in this strong inter-
action between the compound and the protein. K182 interacts
with the protein in amore extended area but in amuchweaker
mode, especially in the hydrophobic core I region; however,
there is no particular fragment of K182 that interacts with the
protein more than the rest. K182’s lack of specificity most
likely contributes to its being a notably weaker compound
than K162. Snapshots shown in Fig. S1 of the Supporting
Material illustrate the interactions in the first four populated
clusters and provide a consistent view of the interacting
modes between each compound and Ab42 monomer.
The LRL22 and LRL27 compounds are structurally very
similar to each other, but they behave differently when they
interact with the protein. To investigate this issue, we per-
formed a cluster analysis on the conformations of these
two compounds using the heavy atoms in regions II and
III (labeled in Fig. 4). As shown in Fig. 5, the most popu-
lated clusters of LRL22, which account for 98% of the
conformational space, have structures in which the two rings
are flexible enough to adopt more conformations and do not
form an intramolecular hydrogen bond. In contrast, LRL27
mainly adopts a conformation in which the bromine atom in
region III forms contact with the region II benzene ring.
This conformation causes the two rings to be closer to
each other and likely more rigid. As a result, the bromine
atom has less chance to interact with the protein.Interaction between the Ab oligomer
and the drug candidates
We carried out four sets of simulations to study the effects of
each organic compound on the oligomer. We also performed
simulations on the Ab oligomer alone to assess its stability
in water and use it as a control for the other four systems. In
an oligomer, the most important feature is the backbone
hydrogen bonds between the neighboring b hairpins. ThereFIGURE 5 The three most populated clusters adopted by (a) LRL22 and
(b) LRL27 during the simulations.
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1080 Li et al.are four interstrand backbone hydrogen bond groups in
a pentamer. We calculated the average number of interstrand
hydrogen bonds between the adjacent strands (Fig. 6). In the
absence of the compounds, the number of backbone
hydrogen bonds did not decrease significantly during the
simulation. This suggests that the oligomer is reasonably
stable in aqueous solution without the compounds. This
was consistent in all four interstrand backbone hydrogen
bond groups. In the presence of any of the four compounds,
the first three groups of backbone hydrogen bonds were
reduced, but by only a small number (<30%) compared
with the oligomer alone. Backbone hydrogen bonds in the
fourth group behaved more similarly to those in the olig-
omer alone without the organic compounds. Of more impor-
tance, all four compounds exhibited a similar effect on the
oligomer, in that the stable oligomer structure was only
slightly more disturbed when any of the four compounds
was present. Maps of the interactions between each
compound and Ab oligomer are shown in Fig. S3. The inter-
actions were broken down to the compound and individual
b strand. The definition of an interaction was the same as
used for the interaction map between the compounds and
Ab42 monomer. All compounds showed a slight preference
to interact with the b-strand regions of the oligomer as
opposed to the turn regions. However, there was no signifi-
cant difference from one compound to another. This is
consistent with the result that all compounds had a similar
effect on the structure of the Ab oligomer.
As noted above, our results regarding interactions
between the drug compounds and the Ab oligomer are
limited by the fact that a consensus on the structure of Ab0 20 40 60 80
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FIGURE 6 The number of backbone hydrogen bonds between the neigh-
boring b hairpins in oligomer with LRL22 (red), LRL27 (blue), K162
(green), K182 (yellow), and without any compound (black). From left to
right and top to bottom are respectively hydrogen bonds between the
first and second, second and third, third and fourth, and fourth and fifth
b hairpins.
Biophysical Journal 100(4) 1076–1082oligomer has not been established. Our results showed
only one special case in which the Ab oligomer had
a cross-b-pattern structure. Future discoveries about the
Ab oligomer structure are essential to provide a more solid
foundation for studying the interaction between drug candi-
dates and the Ab oligomer, as well as for setting the direc-
tion for next-generation drug design.Binding free energy between the drug
compounds and Ab
The binding free energy between Ab and the drug
compounds is not clearly defined, given the above finding
that they interact with each other in a more stochastic
fashion than do proteins and ligands. We estimated the
binding free energy of the drug compounds to Ab oligomer
or monomer by performing molecular mechanics general-
ized Born surface area (MM/GBSA) calculations (48) on
snapshots taken every 0.5 ns from the simulation. Because
the MD simulations were run with more than one drug
compound molecule present, each snapshot generates a cor-
responding number of Ab-drug complexes, among which
the Ab conformation is identical and the drug compounds
sample different orientations. Therefore, the conformations
are sampled in terms of both Ab and the drug compounds.
The energies are plotted with respect to the minimum
distance from the center of mass of the drug compounds
to Ab (Fig. S2) for each complex. The bounded state is
considered to have a distance of<8.0 A˚, and the unbounded
state has a distance of >15.0 A˚. The results are shown in
Table 1. For comparison, the experimental measurement
of the EC50 data is also shown.
For the Ab oligomer, the binding free energies are similar
between LRL22 and LRL27. The two K-series compounds
exhibit a notable difference in their binding free energies,
with K182 more favorable than K162 by ~6.6 kcal/mole.
In the case of Ab monomer, the binding free energies
calculated by average are similar for LRL22 and LRL27,TABLE 1 Binding free energies of drug-Ab monomer and
drug-Ab oligomer
LRL22 (H. S. Hong,
R. Liu, K. S. Lam,
and L. W. Jin,
unpublished)
LRL27
(32)
K162
(33)
K182
(33)
In vitro EC50 (mM) 0.734 >10 0.080 >5.0
Oligomer Average 18.8 19.3 10.2 16.9
Minimum 68.0 70.3 52.9 52.8
Monomer Average 20.8 24.2 10.4 19.5
Minimum 80.8 63.1 55.5 74.0
The free energies were calculated using the MM/GBSA method. The
average energies are the differences between the total energies averaged
over the structures that belong to the bound and free states. The minimum
energies are the lowest binding free energies between the states. Energies
are in units of kcal/mol.
A-b Drug Candidates 1081with LRL27 binding more favorably by 3.3 kcal/mole.
Using the minimum binding energies for the bound and
unbound states, LRL22 displays significantly stronger
binding energy by 17.7 kcal/mol. This, combined with
its preferential interaction in the hydrophobic core I region
(residues 17–21), contributes to its better efficiency in the
experiment. Although K182 exhibits better binding energy
than K162 using both methods, K182 is less efficient than
K162 in the experiment. Because K182 demonstrated no
specificity in interacting with Ab in the hydrophobic core
I region, we conclude that this strong binding energy is
mainly due to interactions that have no effect in stabilizing
the helical conformation in the hydrophobic core I region.
This result further indicates that the specificity in interaction
toward the hydrophobic core I region (residues 17–21) is an
essential factor in designing efficient inhibitors of AD.
The binding free energies of drug-Ab oligomer and drug-
Ab monomer measure the tendency of the drug to form
complexes with Ab. The Ab oligomers are considerably
more stable than the monomers because they benefit from
the backbone hydrogen bonds and side-chain hydrophobic
interactions. It is likely that substantially larger energy
contributions would be required to disrupt the structure of
Ab oligomers, necessitating a higher concentration of
drug compounds or an intrinsically stronger interaction
energy for the Ab oligomer. Given the possible toxicity of
a drug compound at high concentration, an ideal strategy
for designing effective inhibitors of AD would be to induce
specific and strong binding to the hydrophobic core I region
(residues 17–21) to stabilize the Ab monomer, as well as
a strong binding to the Ab oligomer to disassemble it.CONCLUSIONS
In this work, we carried out simulations on oligomers with
and without the presence of compounds. Considering the
special structural property of the oligomers, we focused
our analysis on the number of backbone hydrogen bonds
between two neighbor b hairpins. In the system of the olig-
omer alone, the numbers of backbone hydrogen bonds did
not decrease by much, which suggests that the oligomer
structure is considerably stable in aqueous solution. All
four compounds had similar effect on the oligomer, in that
the stable oligomer structure was only slightly disturbed
when any of the four compounds were present. We note
that because of the lack of information on the Ab oligomer,
this conclusion is biased. More structural information is
necessary to generate a complete picture.
Our simulations on theAb42monomer show that themono-
meric Ab42 protein in water is mainly disordered, which is in
agreement with a previous study (18). An active compound is
able to help theAb42 protein retain a partial helical conforma-
tion. In particular, the helix segment coincided with hydro-
phobic core I (residues 17–21). The more efficient drug
compounds interact with the Ab42 monomer strongly in thehydrophobic core I region. The less active compounds might
also be able to help the Ab protein maintain a certain degree
of helical conformation. However, interactions between a less
active drug compound and the Ab42 monomer were notably
weaker in terms of either lower binding energy or a lack of
preference for the area of interaction. Of more interest,
although the protein does not have a folded structure, some
compounds were able to interact with it in a specific area.
This is in contrast to the normal concept of drug docking in
proteins, and it makes the approach that was used to discover
the active compounds in this work promising for future
attempts to design drugs for AD.
The location of the bromine atom also plays an important
role in interactions between the compounds and the protein.
The only difference between LRL22 and LRL27 is the
position of the bromine atom on the benzene ring. In
LRL27, the bromine is able to form intramolecular contact
with another benzene ring nearby, which leads to rigidity of
the structure and loss of the effect of the bromine on the
protein. Although in LRL22, the bromine atom is less likely
to form intramolecular contacts. As a result, the two
benzene rings are free to move around, which leads to better
interactions with the protein and especially the bromine
atom. The structures of the two fluorene series compounds
are also similar, but to a lesser degree. It seems that the
different electronegativity of oxygen from bromine leads
to varied binding energy to Ab and, more importantly, to
distinct binding sites.SUPPORTING MATERIAL
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